SAN FRANCISCO, May 9 Findings presented at the annual meeting of the American Urological Association (AUA) indicate that prostate cancer could be detected as many as five years earlier than it is currently being diagnosed by testing for a protein in tissue that indicates the presence of early disease. The University of Pittsburgh researchers suggest that testing for the protein, called early prostate cancer antigen (EPCA), could serve as an adjunct to the current diagnostic approach to patients with elevated levels of prostate-specific antigen, or PSA, who undergo repeat needle biopsies. PSA, a substance in the blood released by the prostate gland, is commonly used to check for signs of prostate cancer and other prostate problems. Results are published in abstract 640 of the AUA proceedings.
"One of the problems with testing for levels of PSA as an indicator of prostate cancer is that PSA levels often fluctuate, making it difficult to know for certain whether a man has prostate cancer without performing multiple biopsies over time," said Robert Getzenberg, Ph.D., senior author and professor of urology, pathology and pharmacology at the University of Pittsburgh School of Medicine. "By testing for EPCA in men with high levels of PSA, we may be able to detect the presence of prostate cancer earlier, before it is discoverable by biopsy, saving patients the fear and stress of repeat procedures and enabling us to treat the disease sooner."
Dr. Getzenberg explained that EPCA is a marker protein that indicates the earliest changes that occur in cells during the development of cancer.
In the study, Dr. Getzenberg, also co-director of the Prostate and Urologic Cancer Program at the University of Pittsburgh Cancer Institute, and colleagues developed antibodies against EPCA to detect its presence in tissue. They compared 27 non-diseased control tissue samples to 29 tissue samples from patients with prostate cancer who had initial negative biopsies. ThPage: 1 2 Related medicine news :1
Contact: Jocelyn Uhl
University of Pittsburgh Medical Center
. Prostate cancer screening practices examined2
. Prostate cancer screening interval of 4 years misses few cancers, study shows3
. Prostate cancer program at UCLAs Jonsson Cancer Center designated a site of research excellence4
. Prostate cancer survival benefit from combination of androgen suppression and external irradiation5
. Prostate cancer incidence trends reveal extent of screening-related overdiagnosis6
. Prostate cancer is costly for Californians, according to UCSF researchers7
. Prostate cancer hormonal therapy may increase sexual and physical problems8
. UCSF Study Shows That An Herbal Therapy Reduces PSA Levels By Half In Men With Advanced Prostate Cancer9
. Jefferson Researchers Report First Evidence Of Radiation Therapy Preventing Prostate Cancer Patients From Dying10
. New Method Assesses Risk Of Advanced Cancer After Prostate Removal11
. Cedars-Sinai Medical Center Now Offers Microwave Thermotherapy For Treatment Of Prostate Disease